FDA Provides Clarity To Isis Regarding The Development Path For Mipomersen
May 15th 2008Drug InformationCholesterol
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and Genzyme Corp. (Nasdaq: GENZ) announced that the FDA has provided guidance regarding approval requirements for mipomersen. The FDA has indicated that reduction of LDL-cholesterol is an acceptable surrogate endpoint for accelerated approval of mipomersen for use in patients with homozygous familial hypercholesterolemia (hoFH).
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
